BSR DMARD monitoring guidelines: sulfasalazine
نویسندگان
چکیده
منابع مشابه
Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.
متن کاملWhen a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
OBJECTIVE To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to leflunomide monotherapy. METHODS Patients with active RA ((DAS28) >3.2) who were enrolled in the first open label phase of the RELIEF study received leflunomide for 24 weeks. Inadequate responders then ...
متن کاملEffectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
OBJECTIVE To compare baseline characteristics, responses and drug survival in patients with early RA starting SSZ or MTX in a real-life setting. METHODS The analyses included DMARD-naïve patients with RA (disease duration ≤ 1 year) starting SSZ or MTX. Three- and 6-month effectiveness was compared by unadjusted analysis and with adjustment for propensity score quintile. In addition, effective...
متن کاملBSR and BHPR guidelines for the management of polymyalgia rheumatica.
PMR is the most common inflammatory rheumatic disease in the elderly and is one of the biggest indications for long-term steroid therapy. There are difficulties in diagnosis, with heterogeneity in presentation, response to steroids and disease course. The aim of these guidelines is a safe and specific diagnostic process for PMR, using continued assessment, and discouragement of hasty initial tr...
متن کاملBSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.
Inflammatory arthritis, and especially rheumatoid arthritis (RA), is common and affects over 1% of the population. Even in the 21st century, the prognosis of RA remains uncertain. It runs a variable and unpredictable course. Several longitudinal studies have demonstrated the progressive course of the disease, leading to joint destruction and deformity and, ultimately, to loss of functional inde...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2008
ISSN: 1462-0324,1462-0332
DOI: 10.1093/rheumatology/ken347